Detection of circulating tumour necrosis factor in systemic histiocytosis.
Maury
C P
CP
Fourth Department of Medicine, University of Helsinki, Finland.
Pettersson
T
T
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D008206:Lymphatic Diseases / Q000097:blood* / Q000188:drug therapy; D008297:Male; D015434:Panniculitis / Q000097:blood*; D011241:Prednisone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014750:Vincristine / Q000627:therapeutic use
D007370:Interferon Type I; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone